• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Photocarcinogenicity of drugs.

作者信息

Stern R S

机构信息

Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

出版信息

Toxicol Lett. 1998 Dec 28;102-103:389-92. doi: 10.1016/s0378-4274(98)00237-9.

DOI:10.1016/s0378-4274(98)00237-9
PMID:10022284
Abstract

A number of commonly used medications including quinolone antibiotics, psoralens and various tetracycline derivatives are photosensitizers. These chemicals enhance the erythema response to sunlight. The effect of such exposures on cancer risk has only been quantified in humans for oral psoralen photochemotherapy (PUVA). The experience of a cohort of 1380 patients followed for more than 20 years who received PUVA therapy for the treatment of psoriasis documents that long-term high dose exposure to PUVA greatly increases the risk of squamous cell carcinoma. After 15 years, the risk of melanoma is also increased among high dose patients. With PUVA therapy, an agent which is immunosuppressive in the skin, induces psoralen DNA adducts, is genotoxic and mutagenic. Substantially increased risk is only observed after many purposeful exposures to ultraviolet and this drug. These data suggest that at least some photosensitizing chemicals can substantially increase the risk of skin cancer in humans, but long-term multiple exposures appear to be necessary for a clinical meaningful increase of risk.

摘要

相似文献

1
Photocarcinogenicity of drugs.
Toxicol Lett. 1998 Dec 28;102-103:389-92. doi: 10.1016/s0378-4274(98)00237-9.
2
The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study.补骨脂素和长波紫外线 A 疗法相关的鳞状细胞癌和基底细胞癌风险:一项 30 年的前瞻性研究。
J Am Acad Dermatol. 2012 Apr;66(4):553-62. doi: 10.1016/j.jaad.2011.04.004. Epub 2012 Jan 20.
3
Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study.口服补骨脂素及紫外线A光(PUVA)治疗银屑病与非黑素瘤皮肤癌的持续风险。PUVA随访研究。
J Natl Cancer Inst. 1998 Sep 2;90(17):1278-84. doi: 10.1093/jnci/90.17.1278.
4
Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study.接受甲氧沙林(补骨脂素)和紫外线A辐射(PUVA)治疗银屑病的患者发生恶性黑色素瘤。PUVA随访研究。
N Engl J Med. 1997 Apr 10;336(15):1041-5. doi: 10.1056/NEJM199704103361501.
5
Side-effects of psoralen photochemotherapy (PUVA).补骨脂素光化学疗法(PUVA)的副作用。
Br J Dermatol. 1990 Jun;122 Suppl 36:117-25. doi: 10.1111/j.1365-2133.1990.tb02889.x.
6
PUVA and skin cancer. A historical cohort study on 492 patients.补骨脂素加紫外线A疗法与皮肤癌。一项针对492名患者的历史性队列研究。
J Am Acad Dermatol. 1992 Feb;26(2 Pt 1):173-7. doi: 10.1016/0190-9622(92)70021-7.
7
Cutaneous squamous-cell carcinoma in patients treated with PUVA.接受补骨脂素加长波紫外线(PUVA)治疗的患者的皮肤鳞状细胞癌
N Engl J Med. 1984 May 3;310(18):1156-61. doi: 10.1056/NEJM198405033101805.
8
Risk of melanoma with psoralen/ultraviolet A therapy for psoriasis. Do the known risks now outweigh the benefits?补骨脂素/紫外线A疗法治疗银屑病时患黑色素瘤的风险。目前已知的风险是否已超过益处?
Drug Saf. 1999 Apr;20(4):289-97. doi: 10.2165/00002018-199920040-00001.
9
Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study.接受补骨脂素加紫外线A照射(PUVA)和环孢素治疗的患者的皮肤鳞状细胞癌:巢式队列交叉研究
Lancet. 2001 Sep 29;358(9287):1042-5. doi: 10.1016/S0140-6736(01)06179-7.
10
Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review.香豆素光化学疗法和窄谱 UV-B 疗法治疗慢性斑块型银屑病的致癌风险:系统文献回顾。
J Eur Acad Dermatol Venereol. 2012 May;26 Suppl 3:22-31. doi: 10.1111/j.1468-3083.2012.04520.x.

引用本文的文献

1
Photosensitizing Drugs and Risk of Skin Cancer in Women-A Prospective Population-Based Study.光敏药物与女性皮肤癌风险——一项基于人群的前瞻性研究
Photodermatol Photoimmunol Photomed. 2025 Mar;41(2):e70013. doi: 10.1111/phpp.70013.
2
The effect of hydrochlorothiazide on the recurrence of nonmelanoma skin cancer: a 7-year retrospective study comprising 300 patients.氢氯噻嗪对非黑素瘤皮肤癌复发的影响:一项包含 300 例患者的 7 年回顾性研究。
Turk J Med Sci. 2023 Jun;53(3):760-752. doi: 10.55730/1300-0144.5638. Epub 2023 Jun 19.
3
Reproductive factors, hormone use, and incidence of melanoma in a cohort of US Radiologic Technologists.
生育因素、激素使用与美国放射技师队列中黑色素瘤的发病风险
Hum Reprod. 2022 May 3;37(5):1059-1068. doi: 10.1093/humrep/deac029.
4
Citrus-Gene interaction and melanoma risk in the UK Biobank.柑橘属水果基因交互作用与英国生物库中黑素瘤风险的相关性研究。
Int J Cancer. 2022 Mar 15;150(6):976-983. doi: 10.1002/ijc.33862. Epub 2021 Nov 6.
5
Ultraviolet Radiation and Basal Cell Carcinoma: An Environmental Perspective.紫外线辐射与基底细胞癌:环境视角。
Front Public Health. 2021 Jul 22;9:666528. doi: 10.3389/fpubh.2021.666528. eCollection 2021.
6
Drug-induced photosensitivity: culprit drugs, potential mechanisms and clinical consequences.药物诱导的光敏性:致病药物、潜在机制和临床后果。
J Dtsch Dermatol Ges. 2021 Jan;19(1):19-29. doi: 10.1111/ddg.14314.
7
Photosensitizing antihypertensive drug use and risk of cutaneous squamous cell carcinoma.光敏性降压药物的使用与皮肤鳞状细胞癌风险。
Br J Dermatol. 2018 Nov;179(5):1088-1094. doi: 10.1111/bjd.16713. Epub 2018 Aug 14.
8
Tetracycline use and risk of incident skin cancer: a prospective study.四环素类药物的使用与皮肤癌发病风险:一项前瞻性研究。
Br J Cancer. 2018 Jan;118(2):294-298. doi: 10.1038/bjc.2017.378. Epub 2017 Oct 26.
9
Use of Antihypertensive Drugs and Risk of Malignant Melanoma: A Meta-analysis of Observational Studies.抗高血压药物的使用与恶性黑色素瘤风险:观察性研究的荟萃分析。
Drug Saf. 2018 Feb;41(2):161-169. doi: 10.1007/s40264-017-0599-x.
10
Melanoma and Non-Melanoma Skin Cancer Associated with Angiotensin-Converting-Enzyme Inhibitors, Angiotensin-Receptor Blockers and Thiazides: A Matched Cohort Study.血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂和噻嗪类药物与黑色素瘤和非黑色素瘤皮肤癌的关系:一项匹配队列研究
Drug Saf. 2017 Mar;40(3):249-255. doi: 10.1007/s40264-016-0487-9.